The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
Zilganersen is an investigational antisense oligonucleotide designed to stop excess GFAP production. The Food and Drug Administration (FDA) has granted Fast Track designation to zilganersen for the ...
The therapy is expected to block abnormal blood vessel growth, limit vascular leakage, and reduce retina damage. The Food and Drug Administration (FDA) has granted Fast Track designation to SAR402663 ...
The Food and Drug Administration will fast-track the development of AC699 for patients with ER-positive, HER2-negative ESR1-mutant advanced or metastatic breast cancer. The Food and Drug ...
Liafensine is an investigational, biomarker-based precision medicine for TRD. The Food and Drug Administration (FDA) has granted Fast Track designation to liafensine (DB104) for patients with ...
In preclinical prostate cancer models, HLD-0915 treatment resulted in tumor shrinkage and declines in prostate-specific antigen. The Food and Drug Administration (FDA) has granted Fast Track ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback